electroCore Inc. (NASDAQ: ECOR) reported full-year 2025 net sales of $32.0 million, representing a 27% increase from $25.2 million in 2024, according to a company statement. The bioelectronic technology company attributed the growth to a 25% increase in U.S. prescription business and a 97% rise in general wellness sales.

The company announced that Chief Executive Officer Dan Goldberger will retire effective April 1, 2026. Joshua Lev will assume the role of interim President while continuing as Chief Financial Officer, and Michael Fox will join as Chief Operating Officer.

Gross profit increased $6.4 million to $27.8 million for 2025, with gross margin improving to 87% from 85% in the prior year. The company's U.S. prescription channel generated $24.1 million in sales, up from $19.3 million in 2024. General wellness sales reached $5.5 million, nearly doubling from $2.8 million in the previous year.

Operating expenses rose to $40.9 million from $33.6 million, primarily due to increased sales and marketing costs of $4.3 million and general administrative expenses of $2.7 million. The company reported a GAAP net loss of $14.0 million, or $1.65 per share, compared to an $11.9 million loss, or $1.59 per share, in 2024.

electroCore ended 2025 with $11.6 million in cash, cash equivalents, and marketable securities, down from $12.2 million at the end of 2024. The company provided 2026 revenue guidance of approximately 30% annual growth over 2025 results.

"We are experiencing robust momentum, and I believe we are very well positioned to define the bioelectronic technology category," said Lev in the company statement.